2.800PLN-2.78%Mkt Cap: 212.16M PLNP/E: —Last update: 2026-06-01
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap212.16M PLN
Enterprise Value308.70M PLN
Revenue (TTM)62.66M PLN
Gross Profit23.56M PLN
Net Income (TTM)-19.93M PLN
Revenue/Share0.8900 PLN
Last Price2.800 PLN
Fiscal Year EndDec 2023
MR QuarterSep 2025
Employees239
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLBMDLB00018
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA19.30
EV/Revenue4.93
P/S3.48
P/B1.56
EPS (TTM)-0.26
EPS (Forward)—
52W Range
2.7203% of range5.570
52W High5.570 PLN
52W Low2.720 PLN
Profitability
Gross Margin56.09%
Oper. Margin-154.61%
EBITDA Margin25.54%
Profit Margin-47.45%
ROE-15.99%
ROA-6.55%
Growth
Revenue Growth-64.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF11.84M PLN
CapEx (TTM)28.04M PLN
FCF Margin-90.83%
FCF Yield-26.82%
Net Debt87.19M PLN
Net Debt/EBITDA5.45
Balance Sheet
Debt/Equity0.68
Current Ratio0.94
Quick Ratio0.58
Book Value/Sh1.845 PLN
Cash/Share0.0050 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.75.77M
Float38.17M
Insiders39.06%
Institutions6.86%
Technical
SMA 503.410 (-17.9%)
SMA 2003.926 (-28.7%)
Beta0.16
S&P 52W Chg27.94%
Avg Vol (30d)81.87K
Avg Vol (10d)65.91K
Technical Indicators
RSI (14)25.0
MACD-0.1410
MACD Signal-0.1390
MACD Hist.-0.0019
BB Upper3.249 PLN
BB Middle3.050 PLN
BB Lower2.851 PLN
BB Width13.05%
ATR (14)0.0977 PLN
Vol Ratio (20d)0.90x